Single-cell studies carried out on four patients treated with Revumenib showed a differentiation continuum that started with immature AML blasts (CD34+/c-kit+), progressed through intermediate blast cells (CD68+, CD11b−, and CD14−), and ended with more differentiated monocytic cells (CD68+, CD11b+, and CD14+); intermediate AML blasts and monocytic cells were enriched in post-treatment samples [100]. This evidence concerns the gene CD68 and acute myeloid leukemia.